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Received May 15, 2012; accepted June 7, 2012AbstractPrimary hyperparathyroidism (PHPT) is a common endocrine disorder in adults in whom the typical presentation is incidentally discovered as
asymptomatic hypercalcemia. PHPT is much less common in children and adolescents, but has greater morbidity in this age group, as most
young patients with PHPT will have symptomatic hypercalcemia or complications such as kidney stones, abdominal pain, and skeletal fragility.
An important feature of PHPT in younger patients is the relatively high prevalence of germline inactivating mutations of the CASR gene, which
encodes the calcium-sensing receptor. Biallelic CASR mutations cause neonatal severe hyperparathyroidism, a life-threatening condition that
presents within days of life with marked hypercalcemia, respiratory distress, failure to thrive, and skeletal demineralization. By contrast, more
common heterozygous CASR mutations are generally associated with a benign variant of PHPT termed familial hypocalciuric hypercalcemia.
Appropriate management of PHPT in children and adolescents requires distinction between familial hypocalciuric hypercalcemia, which
generally requires no specific treatment, and other forms of PHPT that are best treated by parathyroidectomy.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Parathyroid hormone (PTH) is the principal calciotropic
hormone, and its secretion from the parathyroid glands is
tightly controlled by ambient concentrations of extracellular
ionized calcium. PTH secretion is increased by hypocalcemia,
and decreased by hypercalcemia, through interaction of
ionized calcium with calcium-sensing receptors (CaSR) that
are located on the plasma membrane of parathyroid cells. The
hallmark of primary hyperparathyroidism (PHPT) is hyper-
calcemia, which results from the excessive secretion of PTH
by one or more of the four parathyroid glands. PHPT occurs as
a result of a specific defect in a parathyroid gland. Thus, PHPT
is fundamentally distinct from secondary hyperparathy-
roidism, in which increased secretion of PTH is an adaptive* Corresponding author. Dr. Michael A. Levine, Division of Endocrinology
and Diabetes, The Children’s Hospital of Philadelphia, 34th and Civic Center
Boulevard, Philadelphia, PA 19104, USA.
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http://dx.doi.org/10.1016/j.jcma.2012.06.012response to low serum levels of calcium or vitamin D.
Although serum levels of calcium and PTH are both elevated
in patients with tertiary hyperparathyroidism, this condition
reflects a maladaptive response to antecedent hypocalcemia or
vitamin D deficiency.
Our understanding of the natural history and pathophysi-
ology of PHPT has been informed by two revolutionary
events. First, the introduction of the multichannel autoanalyzer
in the early 1970s enabled inexpensive and accurate
biochemical measurement of many serum analytes, and
encouraged routine biochemical screening of healthy adult
patients. The subsequent widespread application of biochem-
ical screening unexpectedly disclosed that large numbers of
patients had asymptomatic hypercalcemia.
Second, a sensitive and reliable immunoassay for intact
PTH (iPTH) was commercialized in the 1980s. This assay
provided the ability to reproducibly distinguish elevated
circulating concentrations of iPTH from normal concentra-
tions. Together, these two laboratory advances transformed
PHPT from a rare clinical disease associated with significanthinese Medical Association. All rights reserved.
Table 1
Sex distribution of NSHPT in infants.
Girard et al6 Mallet13 Total
Males 8/17 4/11 12/28 (43%)
Females 9/17 7/11 16/28 (57%)
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affected patients have few signs or symptoms of excess PTH
or hypercalcemia.1e5 PHPT currently is recognized as the
third most common endocrine disorder in adults. PHPT is most
common in patients who are between the ages of 50 and 60
years, and has an annual incidence of 30 cases per 100,000
patients, with a lifetime prevalence of approximately 1 per
1000 persons. Females outnumber males with PHPT by an
approximate 3:1 ratio.
In contrast with the clinical profile of PHPT in adults,
PHPT is uncommon in infants and children, with an incidence
estimated at only 2-5 in 100,000 and without an apparent sex
predilection (Tables 1 and 2).6e8,10,13e18 Remarkably, PHPT is
clinically symptomatic in most young patients, who typically
present with signs or symptoms of hypercalcemia, skeletal
complications, and/or nephrolithiasis. Few if any young
patients with PHPT are discovered incidentally to have
asymptomatic hypercalcemia. It is unlikely that ascertainment
bias, due to infrequent biochemical testing of children and
adolescents, can explain the absence of asymptomatic PHPT in
younger populations, as PHPT remains uncommon as late as
the fourth and fifth decades of life, a time when adults begin to
undergo routine biochemical screening. Therefore, we propose
that there must be biologic differences that account for the
distinct differences between PHPT in young and older
patients.
Prior to 1984, fewer than 150 children with PHPT had been
described in the literature.6 However, over the past 30 years
several large pediatric case series were published that
increased the number of reported cases of PHPT in this age
group to more than 300.7e18 The largest of the primary studies
in this area comprises 55 patients, of whom 11 were infants
with PHPT and 44 were young children or adolescents with
PHPT.13 The largest study focusing solely on childhood and
adolescent PHPT includes 52 patients.12 Although these
different reports vary in the clinical characterization of PHPT,
our systematic analysis of these series reveals a consistent
description of the important features of pediatric PHPT.
2. Etiology of pediatric PHPT
Genetic syndromes that are associated with multiple
abnormal parathyroid glands may account for 5-15% of allTable 2
Sex distribution in children/adolescents with PHPT.
Girard
et al6
Cronin
et al8
Loh
et al10
Hsu and
Levine17
Venail
et al7
Malle
Males 40/69 5/8 5/7 6/11 1/4 26/44
Females 20/69 3/8 2/7 5/11 3/4 18/44cases of PHPT, and are relatively more common in patients
younger than 40 years than in older patients.19 A growing
number of gene defects have been associated with PHPT, and
in many cases germline or somatic mutations in the same gene
can induce development of either multiple or single para-
thyroid adenomas, respectively. In addition, radiation exposure
increases the risk of developing PHPT. The association
between radiation exposure, either during childhood or
adulthood, and subsequent development of PHPT in later years
has been well established.20,21 By contrast, there is only
a single report of childhood PHPT occurring in association
with previous therapeutic radiation exposure.22 We reviewed
selected features of PHPT in different pediatric age groups,
described in the following sections.2.1. Neonatal severe hyperparathyroidism and familial
hypocalciuric hypercalcemiaPHPT can present within the first few days of life as neonatal
severe hyperparathyroidism (NSHPT; Online Mendelian
Inheritance in Man [OMIM] 239200) an uncommon disorder
that is associated with severe metabolic bone disease and often
life-threatening hypercalcemia (greater than 20 mg/dL). The
diagnosis of NSHPT is based on the presence of elevated PTH
levels along with relative hypocalciuria in an infant with
hypercalcemia. A family history of early-onset hypercalcemia
in a sibling or parent can provide strong confirmation of the
diagnosis. Care must be taken to distinguish these disorders
from the transient neonatal hyperparathyroidism associated
with maternal hypocalcemia, as seen in mothers with severe
vitamin D deficiency or hypoparathyroidism. In all cases that
have been analyzed, NSHPT has been associated with inacti-
vating mutations in the CASR gene (http://www.casrdb.mcgill.
ca/) located at 3p13.3 (OMIM 601198). The CASR gene
encodes CaSR, which is a member of family C of the hepta-
helical G-protein-coupled receptors (GPCRs) that also includes
themetabotropic glutamate receptors (mGluR), g-aminobutyric
acid (GABA)B receptors, and many olfactory, pheromone, and
taste receptors (www.GPCR.org). The CaSR is widely distrib-
uted throughout the body, but its principal function appears
related to regulation of calcium homeostasis through its
expression on the plasma membranes of parathyroid and renal
tubule cells. Activation of the parathyroid CaSR by extracel-
lular ionized calcium (Ca2þ) inhibits secretion of PTH, while in
the distal renal tubule cells receptor activation leads to enhanced
urinary excretion of calcium.
In most cases, neonates with NSHPT have inactivating
mutations on both CASR alleles, which results in a complete or
near-complete absence of functional CaSRs on parathyroid
and other cells in the body. The loss of calcium sensing leadst13 Bhadada
et al14
George
et al15
Durkin
et al18
Li et al16 Proportion
(percentage)
6/14 4/18 3/12 5/12 101/199 (51%)
8/14 14/18 9/12 7/12 98/199 (49%)
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well as decreased renal excretion of calcium, and consequently
severe hypercalcemia ensues. Some infants with NSHPT have
been described who possess only a single defective CASR
allele. In these cases the mutant CASR was inherited from an
affected father or arose as a de novo mutation. Presumably,
exposure of the affected fetus to normal maternal calcium
concentrations intensifies development of hyperparathy-
roidism in utero and leads to severe hypercalcemia after
birth.23e27 Other NSHPT infants with monoallelic CASR
mutations have de novo or paternally inherited CASR missense
mutations that replace the normal arginine at codon 185 with
a glutamine residue (R185Q).26,28e30 The R185Q mutation is
particularly significant because it acts as a dominant inhibitor,
thereby suppressing function of the normal CaSRs that are
produced by the wild type CASR allele.
Although heterozygous CASR mutations can cause NSHPT,
monoallelic mutations are more commonly associated with
a relatively asymptomatic form of PHPT that has been termed
familial hypocalciuric hypercalcemia (FHH), sometimes also
termed benign familial hypercalcemia (FHH/HHC1; OMIM
145979). FHH is therefore genetically related to NSHPT and
its mildness is thought to represent a dose affect of the inac-
tivating CASR mutations. Hence, FHH is typically an auto-
somal dominant condition,31,32 although very mild CASR
mutations have been associated with an autosomal recessive
form of FHH.33 In both FHH and NSHPT, hypercalcemia
arises due to decreased calcium sensing in the parathyroid
glands, the kidney, the skeleton, and perhaps other tissues.34
Specifically, lack of calcium-mediated signaling leads to
enlargement of all four (or more) parathyroid glands and either
modest (FHH) or markedly (NSHPT) increased secretion of
PTH. Concurrently, the fractional renal clearance of calcium
(FeCa) is reduced to less than 1% due to the loss of CaSR
action in the distal renal tubule. Increased circulating
concentrations of PTH act on the kidney and skeleton to
increase serum calcium. This effect, combined with decreased
renal calcium clearance and possibly decreased secretion of
calcitonin, leads to the development of severe hypercalcemia
and metabolic bone disease in NSHPT and only mild (and
generally asymptomatic) hypercalcemia in FHH.352.2. Childhood/adolescent PHPTChildhood/adolescent PHPT is associated with either single
parathyroid adenomas or multiple adenomas (so-calledTable 3
Clinical and molecular features of genetic syndromes of primary hyperparathyroid
FHH MEN1
Tissues affected Parathyroid Parathyroid
Kidney Pituitary
Pancreas
Gene defect CaSR MEN1 gene
11q13
*CDKN1B P27kip
FIHP ¼ familial isolated hyperparathyroidism; FHH ¼ familial hypocalciuric h
endocrine neoplasia.parathyroid hyperplasia). In many cases the precise molecular
defect can be identified, and is either a somatic mutation that is
limited to the parathyroid adenoma or a germline mutation that
was inherited or arose de novo in the parathyroid gland. Thus,
the etiology of PHPT includes (1) multigland hyperplasia
resulting from germline mutations in the MENIN, RET, and
CDKN1B (encoding p27Kip1) genes; (2) single parathyroid
adenomas that represent monoclonal neoplasms, many of
which are associated with somatic mutation in MENIN or
PRAD1; and (3) distinct parathyroid adenomas due to germ-
line or somatic mutations in HPRT2 (CDC 73) and which have
a predisposition to parathyroid carcinoma (Table 3).
FHH must be distinguished from other forms of PHPT in
this age group, because FHH is usually an asymptomatic
condition and is managed differently from true PHPT. In
contrast with most patients with PHPT, patients with FHH
have circulating concentrations of PTH that are normal or only
slightly elevated. However, in the presence of hypercalcemia
such concentrations are inappropriately high and indicate that
the set-point of the parathyroid calciostat regulating PTH
secretion functions at a higher than normal level (see previous
paragraph). The hypercalcemia and hypophosphatemia are
similar in magnitude to those found in mild cases of PHPT.
Most patients have no symptoms attributable to the hyper-
calcemia, although it is rare that patients experience mild
muscle weakness and easy fatiguability. In contrast with
patients with PHPT, patients with FHH tend to have elevated
plasma levels of magnesium. The key diagnostic feature of
FHH is the very low (i.e. generally less than 1%) fractional
excretion of calcium (FeCa) by the kidney. However, normal
or even elevated urinary calcium excretion has been described
in members of several FHH kindreds,36,37 and hypocalciuria
can be present in some patients with common PHPT who also
have vitamin D insufficiency. Therefore, hypocalciuria is not
an absolute criterion. The urinary calcium excretion is usually
less than 100 mg/24 hour (25 mmol/24 hour), in contrast with
true PHPT, where it is usually greater than 120 mg/24 hours.
The plasma level of calcitriol in FHH is usually in the mid-
normal range in contrast to a tendency to elevated levels in
PHPT. Further confusion between FHH and PHPT derives
from recent reports of the development of classic parathyroid
adenomas and symptomatic PHPT in some teens and adults
with FHH, however.38,39
Multiple endocrine neoplasia, or MEN1 (OMIM 131099),
is the most common cause of inherited PHPT. PHPT is present
in more than 90% of patients, and diffuse hyperplasia orism.
MEN2a HPT-JT FIHP
MTC Pheo Parathyroid Parathyroid
Parathyroid Jaw
Kidney
Ret HPRT2 gene Rarely HPRT2 gene;
most unknown1q25
ypercalcemia; HPT-JT ¼ hyperparathyroidism-jaw tumor; MEN ¼ multiple
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PHPT is rare in the first decade of life. Pancreatic islet cell
tumors occur in 60-70% of patients and are usually multi-
centric. Multiple adenomas or diffuse islet cell hyperplasia
commonly occurs, and approximately 30% of tumors are
malignant and have local or distant metastases. Approximately
40% of islet cell tumors are insulinomas, which are more
common in patients younger than 40 years. Approximately
60% of islet cell tumors originate from non-b-cell elements
and tend to occur in patients older than 40 years. Pituitary
tumors occur in 15-42% of MEN1 patients. Prolactinomas are
the most common pituitary tumors, and approximately 25% of
pituitary tumors secrete growth hormone or growth hormone
and prolactin. Additional features of MEN1 include carcinoid
tumors, particularly those derived from the embryologic
foregut, and subcutaneous and visceral lipomas, angiofi-
bromas, and collagenomas. Some patients with MEN1 who do
not have mutations in MENIN may have mutations in
CDKN1B, which encodes cyclin-dependent kinase inhibitor
1B. This enzyme belongs to the Cip/Kip family of cyclin
dependent kinase (Cdk) inhibitor proteins.
PHPT is relatively uncommon in MEN2a (OMIM 171399),
occurring in only 20- 30% of patients, and almost never occurs
in MEN2b (OMIM 162299). Generally all four parathyroid
glands are affected, but metasynchronous or asynchronous
parathyroid involvement is common. PHPT is usually diag-
nosed after the third decade of life, and although it can occur
in children this is a rare finding. PHPT is less severe in MEN2a
than in MEN1. The highest prevalence of PHPT occurs in
patients who carry the codon 634 RET gene mutation.
Medullary thyroid carcinoma is the most common feature of
MEN2a, occurring in more than 90% of patients. Pheochro-
mocytoma occurs in approximately 50% of patients.
Germline mutations of the HRPT2 gene cause the
hyperparathyroidism-jaw tumor (HPT-JT) syndrome (OMIM
145010).40,41 HPT-JT is an uncommon autosomal dominant
syndrome characterized by PHPT due to parathyroid
adenomas and fibro-osseous lesions of the maxilla and
mandible. Patients with HPT-JT may also develop otherTable 4
Parathyroid histology in children/adolescents with primary hyperparathyroidism.
Girard
et al6
Cronin
et al8
Lawson
et al9
Loh
et al10
Hsu and
Levine17
Kollars et al12
Hyperplasia* 3/68 1/8 0/11 1/7 1/11 3/52
Adenoma 54/68 7/8 11/11 6/7 10/11 36/52
MEN 1 NA NA NA NA NA 10/52
(hyperplasia in 8
MEN2a NA NA NA NA 1/11 3/52
(hyperplasia in 3
Familial HPT NA NA NA NA NA 3/52
(hyperplasia in 1
Not reported 11/68 NA NA NA NA NA
No pathology
identified
on exploration
NA NA NA NA NA 4/52
* Most of these cases occurred in series where the patients MEN1 or MEN2a gen
categories. However, in the series by Kollars et al, they found three cases of apparen
or represent misdiagnosed tertiary hyperparathyroidism. HPT ¼ hyperparathyroidimanifestations including renal tumors and cysts and uterine
tumors. The syndrome typically develops in late adolescence
or early adulthood. Parathyroid tumors, most often single
adenomas, occur in up to 95% of patients with HPT-JT.
Parathyroid carcinoma occurs in approximately 15% of
cases. Some patients with familial isolated PHPT also have
HRPT2 mutations.
Interestingly, somatic mutations in some of the genes
implicated in multiglandular PHPT (MENIN, HPRT2, and
CDKN1B) can cause solitary parathyroid adenomas when they
occur as somatic mutations. This occurrence serves to empha-
size that the histologic distinction between parathyroid
adenoma and parathyroid hyperplasia may not be real, and
certainly is not useful in predicting single versus multiple gland
disease as both variants can arise from the same mutation.
3. Pathology
In most cases, PHPT will result from a single benign
parathyroid adenoma (90%); multiple adenomas occur rarely
(approximately 2-4%). Involvement of all four parathyroid
glands, so-called parathyroid hyperplasia, occurs in approxi-
mately 10% of patients, but may be metasynchronous or
asynchronous. Parathyroid carcinoma is exceedingly
uncommon (less than 1%).3.1. Neonatal severe hyperparathyroidism and familial
hypocalciuric hypercalcemiaTraditionally, the abnormal parathyroid glands in NSHPT
and FHH have been described as hyperplastic, but this char-
acterization may have been based on enlargement of all four
(or more) glands rather than specific histologic features. The
abnormal glands are benign tumors.3.2. Childhood/adolescent PHPTMost cases of childhood/adolescent PHPT, like adult PHPT,
are associated with a single parathyroid adenoma (196 of 213;Venail
et al7
Mallet 13 George
et al15
Bhadada
et al14
Durkin
et al18
Li
et al16
Proportion (%)
0/4 11/40 0/18 1/14 3/12 0/12 21/225 (9%)
4/4 29/40 18/18 12/14 9/12 12/12 208/225 (92%)
/10)
NA 2/40 NA NA NA NA 16/105 (15%)
/3)
NA NA NA NA NA NA 5/63 (8%)
/3)
NA NA NA NA NA NA 3/52 (6%)
NA 8/40 NA NA NA NA 11/213 (5%)
NA NA NA NA NA NA 4/52 (8%)
otype was not reported; it is likely that most of these cases fall into these two
t primary hyperparathyroidism. It is possible that these are somatic mutations,
sm; MEN ¼ multiple endocrine neoplasia; NA ¼ not applicable.
Table 5
Clinical characteristics of infants with neonatal severe hyperparathyroidism (reported in two studies, n ¼ 23).
Norwood et al44 Mallet13 Proportion (percentage)
Failure to thrive/feeding difficulties 8/12 2/11 10/23 (43%)
Skeletal abnormalities (fractures, thoracic deformities,
metaphysic irregularities, cortical dualization,
subperiosteal erosion)
9/12 10/11 19/23 (83%)
Hyaline membrane disease/respiratory distress 2/12 3/11 5/23 (22%)
Premature birth 2/12 NA 2/12 (17%)
Hypotonia NA 6/11 6/11 (55%)
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usually have germline mutations associated with genetic
syndromes such as MEN1 and MEN2a as well as familial
hyperparathyroidism. In nearly all cases, including children
with HPT-JT syndrome, the parathyroid tumors are benign.
Parathyroid carcinoma occurs in fewer than 1% of parathyroid
tumors in adults,42 and is usually associated with either
somatic or germline mutations in HPRT2 (CDC 73).434. Clinical features/complications4.1. Neonatal severe hyperparathyroidismThe clinical features of NSHPT include failure to thrive,
hypotonia, respiratory distress, and prominent skeletal
involvement. Serum levels of intact PTH and calcium are
markedly elevated, and marked bone demineralization or
fractures are present at birth or soon thereafter. Hypercalcemia
often requires urgent intervention.
Three series of patients with NSHPT have been pub-
lished.6,13,44 Of these series, two studies are compilations of
previously published patients6,44 and Mallet’s series13 is
a primary study. At diagnosis, the most common clinical
characteristics in patients described in these series (Table
5)12,13 were skeletal abnormalities (82%), followed by hypo-
tonia (55%) and failure to thrive (43%).4.2. Childhood/adolescent PHPTAs described previously, childhood/adolescent PHPT often
presents with vague symptoms. These symptoms usuallyTable 6
Clinical characteristics of children/adolescents with primary hyperparathyroidism.
Huang
et al11
Cronin
et al8
Lawson
et al9
Loh
et al10
Mayo (1999)11 Hsu an
Levine1
Kidney stones 20/74 NA 7/11 1/7 14/33 7/11
Hypercalciuria 39/74 NA NA NA NA 9/10
Bone disease 33/74 NA 7/11 NA 9/33 2/7
Abdominal
pain/vomiting
3/74 7/8 NA 2/7 NA NA
Hypertension 6/74 NA NA 1/7 NA NA
Vague symptoms NA NA 10/11 3/7 7/33 1/11
Hypercalcemic crisis NA 4/8 NA NA NA NA
Asymptomatic NA 1/8
(MEN2a)
1/11 NA 6/33 (18%) 2/11 (1include bone pain and abdominal pain. In recent series,
however, almost 15% of patients have lacked symptoms at the
time of diagnosis, with PHPT diagnosis following incidentally
discovered hypercalcemia (Table 6)7e18. Despite this group of
patients reportedly having few or no symptoms, most of these
patients showed skeletal (88 of 117; 75%) or renal (60 of 134;
45%) pathology (Table 7)7,9,12e14,16. Biochemically, these
patients manifest hypercalcemia, hypophosphatemia hyper-
calciuria, and either elevated or inappropriately normal
concentrations of iPTH (Table 8)7e18. In contrast with adult
PHPT, in which an approximate 3:1 female predominance
occurs, sex distribution appears to be nearly equal in pediatric
PHPT (Table 2).5. Ascertainment and diagnosis
The critical biochemical features of PHPT are an elevated
(or inappropriately normal) level of serum iPTH in the context
of a high-normal or elevated serum calcium concentration.
FHH and NSHPT are characterized by very low urinary
calcium excretion (fractional excretion of calcium (FeCa) of
less than 1%),45e48 whereas other forms of PHPT usually have
higher levels of urinary calcium (FeCa greater than 1%). Urine
levels of calcium can be low in some patients with PHPT,
particularly when there is coexisting vitamin D insufficiency.
Many patients with FHH or NSHPT will also have an affected
first-degree relative.
Both NSHPT and PHPT in childhood/adolescence usually
present with clinically significant morbidity; patients with
FHH are generally asymptomatic and a diagnosis is made
either on the basis of an affected family member or thed
7
Kollars
et al12
Venail
et al7
Mallet13 Bhadada
et al14
George
et al15
Li
et al16
Proportion
(percentage)
21/ 52 0/4 18/44 7/14 6/18 9/12 110/280 (39%)
NA NA 32/44 NA NA NA 80/134 (60%)
18/52 4/4 7/44 10/14 16/18 11/12 117/269 (43%)
15/52 3/4 2/44 NA NA 4/12 32/189 (17%)
NA NA NA NA NA 1/12 8/93 (9%)
NA NA 8/44 NA NA 6/12 49/140 (35%)
NA 0/4 1/44 NA NA 1/12 6/68 (9%)
8%) 11/ 52 0/4 8/44 1/14 (MEN) NA 0/12 29/211 (14%)
Table 7
End-organ effects in children/adolescents with primary hyperparathyroidism.
Lawson et al9 Kollars et al12 Venail et al7 Mallet13 Bhadada et al14 Li et al16 Proportion (percentage)
Bone abnormalities 8/11 11/32 4/4 44/44 10/14 11/12 88/117 (75%)
Nephrocalcinosis or
nephrolithiasis
by US or X-ray
8/11 17/52 2/4 13/44 11/14 9/12 60/134 (45%)
Band keratopathy 2/6 NA NA NA NA NA 2/6 (33%)
Acute pancreatitis NA 4/52 0/4 NA 2/14 1/12 7/82 (9%)
NA = not applicable; US = ultrasound.
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biochemical screening for an unrelated condition. In NSHPT
the symptoms are often vague and include failure to thrive,
respiratory distress, or severe metabolic bone disease. Patients
with childhood or adolescent PHPT tend to have signs or
symptoms of hyperparathyroidism or hypercalcemia at the
time of initial presentation, with our assessment of recent
publications (summarized in Table 6) indicating that only
approximately 15% of patients are asymptomatic. By contrast,
more than 80% of adults with PHPT are asymptomatic.49
Classically, the symptoms reported by children or adoles-
cents with PHPT are conveniently recalled using the phrase
“stones, bones, abdominal groans, thrones, and psychiatric
overtones." These terms refer to kidney stones, metabolic bone
disease (reduced bone density, fractures, or rarely osteitis fibrosa
cystic), abdominal pain (due to gastric hyperacidity, pancrea-
titis, or constipation), polyuria, and cognitive or psychiatric
dysfunction. However, pediatric case reports also describe
a wide range of additional vague or nonspecific features.
The biochemical features of pediatric PHPT mirror those of
the adult form; patients have hypercalciuria, hypercalcemia,
hypophosphatemia, and either inappropriately normal or
elevated iPTH concentrations in the context of hypercalcemia.
In recent large studies investigating the changing biochemistry
of PHPT in adults, the serum calcium, serum ionized calcium,
and serum PTH concentrations at presentation for surgery
were 2.8 mmol/L (normal range 2.1-2.6),50 1.45 nmol/L
(normal range 1.15-1.2), and 103 pg/mL (normal range 15-65),
respectively.51 For comparison, in the studies reviewed here,
the average serum calcium, serum ionized calcium, and serum
PTH concentrations at presentation in children and adolescents
were 3.27 mmol/L (n ¼ 226, normal range 2.1-2.6),
1.56 nmol/L (n ¼ 59, normal range 1.15-1.2), and 200 pg/mL
(n ¼ 156, normal range 10-70), respectively. The increased
magnitude of deviation from the normal range observed in
childhood and adolescent PHPT biochemical measurements is
consistent with the idea that PHPT is more severe in children
and adolescents than in adults.6. Management and outcome6.1. Neonatal severe hyperparathyroidismEarly surgical intervention with subtotal parathyroidectomy
was the standard treatment of NSHPT before the invention of
potent intravenous bisphosphonates.52 Although surgeryremains curative for this disease, however, total resection of all
enlarged parathyroid glands leads to hypoparathyroidism.
Evidence suggests that in many cases of NSHPT surgery can be
postponed or obviated through the use of intravenous
bisphosphonates to reduce serum calcium.29,52 An alternative
that has reported with less success is treatment with a calcium-
poor diet concurrent with close biochemical monitoring.
Interestingly, recent studies in a single adolescent53 and in adult
patients54 with PHPT have shown that mild hypercalcemia can
be managed using type II calcimimetic compounds. Although
type I calcimimetics are direct receptor agonists, type II calci-
mimetics (such as cinacalcet) are allosteric modifiers that
reduce the threshold for CaSR activation by Ca2þ by increasing
the affinity of the receptor for calcium. Recent case reports
suggest a role for these agents as medical alternatives or
adjuncts to surgery or bisphosphonates to control hypercal-
cemia in neonates and infants with NSHPT due to heterozygous
inactivating mutations of the CASR gene.28,30 Although calci-
mimetics are able to control hypercalcemia, the long-term
effects of these agents on skeletal integrity remain unknown.
Some studies of these compounds in experimental animal
models of hyperparathyroidism imply that calcimimetics may
contribute to structural bone disease despite normalizing serum
calcium and PTH concentrations.55,566.2. Childhood/adolescent PHPTSurgery is curative in most pediatric and adult patients with
PHPT, although patients with MEN1 will usually require more
than one surgery when initial parathyroidectomy is conserva-
tive (Table 9)7,9e16. The preoperative identification of a single
parathyroid adenoma, usually by 99 m Tc-sestamibi scan or
neck ultrasonography, allows consideration of minimally
invasive parathyroid surgery instead of a conventional bilateral
neck exploration. Sestamibi is absorbed faster by a hyper-
functioning parathyroid gland than by a normal parathyroid
gland. Moreover, sestamibi is retained by an abnormal para-
thyroid gland for a longer period of time than by the
surrounding normal thyroid tissue. Uptake of sestamibi
correlates with the number and activity of the mitochondria
within the parathyroid cells. Hence, chief cell parathyroid
adenomas have a very high avidity for sestamibi, whereas
oxyphil/clear cell parathyroid adenomas have almost no
imaging quality at all with sestamibi. Approximately 60-80%
of parathyroid adenomas can be identified by sestamibi
scanning. Specific limitations to success include
Table 8
Biochemical characteristics of children/adolescents with primary hyperparathyroidism.
Cronin et al8
(n ¼ 8)
Lawson et al9
(n ¼ 11)
Loh et al10
(n ¼ 7)
Harman et al11
(n ¼ 33)
Hsu and
Levine17
(n ¼ 11)
Kollars et al12
(n ¼ 52) (12)
Venail et al7
(n ¼ 4)
Mallet13
(n ¼ 44)
Bhadada
et al14
(n ¼ 14)
Geor tal15
(n ¼ )
Durkin et al18
(n ¼ 12)
Li et al16 Average, (n)
Mean Ca in
mmol/L
(range or SD),
normal
range 2.1-2.6
3.4 (2.39-
4.58)
3.39 (2.64-4.2) 3.26
(SD 0.43)
3.025
(2.55-4.55)
(100%)
2.98
(2.65-3.45)
2.93 (2.5-4.0) 3.79
(2.96-4.34)
3.27
(2.6-4.33)
2.78
(2.12-3.4)
3.35
(SD )
3.18
(2.73-3.98)
3.82
(3.3-5)
3.27,
n ¼ 226
iCa in nmol/L,
(range or SD),
normal
range 1.15-1.2
NA 1.66 (range
1.5-2.24 n ¼ 7)
NA NA NA 1.55 n ¼ 52 NA NA NA NA NA NA 1.56,
n ¼ 59
Mean Phosphorus
in mg/dL
(range or SD),
normal
range 4.9-5.5
NA 3.36 (2.1-8.07) NA 2.9 (1.9-4.1) NA 2.9 (1.8-5.3) NA NA 2.8
(1.7-3.6)
1.96
(SD )
NA 3.65
(1.9-5.44)
2.86,
n ¼ 140
Urinary Ca in
mg/24 hr,
normal
range 0-250
NA NA NA 397 (119-1370),
n ¼ 33
NA NA NA NA NA NA NA NA 397
n ¼ 33
PTH (pmol/L)
normal
range 1-5.2
NA NA NA 9.9 (2.7-34),
n ¼ 12
NA 8.1 (3.1-34),
n ¼ 52
NA NA NA NA NA NA 8.8,
n ¼ 64
PTH (pg/mL)
(range or SD),
normal
range 10-70
NA 390 (79-930),
n ¼ 7
339
(SD 623),
n ¼ 7
221 (27-1700),
n ¼ 21
110
(31-165)
n ¼ 9
58 (19-1700),
n ¼ 52
82.9
(87-1580),
n ¼ 4
NA 78.1
(SD 586),
n ¼ 14
80.1
(SD )
(RIA
n ¼
187 (77-300),
n ¼ 12
1016
(105-2800),
n ¼ 12
200,
n ¼ 156
Ca ¼ calcium; iCa ¼ ionized calcium; NA ¼ not applicable; PTH ¼ parathyroid hormone; SD ¼ Standard deviation.
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Table 9
Postoperative complications (reported in 9 of 11 studies, n ¼ 161).
Lawson
et al9
Loh
et al10
Harman
et al11
Kollars
et al12
Venail
et al7
Bhadada
et al14
Mallet13 George
et al15
Li
et al16
Proportion (%)
Acute hypocalcemia 7/9 NA 1/31 29/52 2/4 10/13 NA 8/18 10/12 67/137 (49%)
Persistent hypocalcemia NA 1/22 NA 1/52 0/4 NA NA NA 0/12 2/90 (2%)
Failed initial surgery NA NA 15% 9/52 0/4 NA 5/44 1/18 0/12 20/161 (12%)
Persistent hypercalcemia NA NA NA 3/52 0/4 NA NA NA 0/12 3/68 (4%)
Spontaneous remission
without surgery
NA NA 1/2 NA NA NA NA NA NA 1/2 (50%)
Hungry bone syndrome NA NA NA NA 2/4 10/13 NA 5/18 NA 17/35 (49%)
NA ¼ not applicable.
432 J. Roizen, M.A. Levine / Journal of the Chinese Medical Association 75 (2012) 425e434multiglandular parathyroid disease and a small parathyroid
adenoma. The use of single-photon emission computed
tomography (three dimensional) as an adjunct to planar
methods appears to increase sensitivity and accuracy, espe-
cially in cases of small parathyroid adenomas or adenomas
that are located in ectopic sites. In most centers, minimally
invasive parathyroid surgery is performed using intraoperative
measurement of PTH levels to confirm successful
parathyroidectomy.7. Outcomes7.1. Neonatal severe hyperparathyroidismDescriptions of NSHPT that were published before the
introduction of automated methods for measurement of serum
calcium in 1984 reported mortality rates of approximately
50% (Table 10)6,13. In fact, almost half of these deaths, or 25%
of total reported cases, occurred in infants who did not have
a diagnosis of hypercalcemia prior to death. By contrast, the
most recent series on NSHPT report no mortality among
patients with NSHPT.13 Thus, improved outcomes in NSHPT
have resulted from the availability of simple assays for serum
calcium, and the common practice of measuring serum
calcium concentrations in infants who are failing to thrive. In
neonates of parents with FHH, early screening of serum
calcium allows rapid diagnosis and early initiation of treat-
ment. A mutation in the CASR gene is the cause of most cases
of NSHPT,23e27 and was identified in 75% of infants with
neonatal PHPT reviewed here.7.2. Childhood/adolescent PHPTParathyroidectomy is the treatment of choice in children
with PHPT. Because PHPT is generally more severe in this age
group, children are at significant risk of postoperative hungryTable 10
Treatment and outcomes in infants with neonatal severe hyperparathyroidism.
Girard et al6 Mallet13 Total
Surgery 11/17 11/11 22/28 (76%)
Fatal (with surgery) 3/9 0/11 3/20 (15%)
Fatal (diagnosis at autopsy) 8/8 0/11 8/19 (42%)bone syndrome (approximately 50%) and acute hypocalcemia
(Table 9 e nearly 50%). In addition, some patients will
develop either persistent hypocalcemia (2%) or hypercalcemia
(3%). Finally, although bone mass improves significantly in
adults after successful parathyroidectomy,57,58 similar studies
in pediatric patients with PHPT are lacking.
In conclusion, PHPT is far less common in the pediatric
population than in the adult population, and likely constitutes
less than 5% of all cases of PHPT.10 PHPT appears to be
a more aggressive disorder in children than in adults, in whom
most cases currently are incidentally ascertained by routine
biochemical screening. In the context of hypercalcemia and
suspicion of PHPT, it is important to exclude the diagnosis of
FHH, as patients with this disorder will generally not benefit
from surgical intervention. When surgical management is
indicated, we recommend that parathyroidectomy be per-
formed in a large-volume center by an experienced surgeon to
enhance the probability of cure.
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